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The Alzheimer’s disease-associated presenilin (PS) 1 is
intimately involved in -secretase cleavage of -amyloid
precursor protein and other proteins. In addition, PS1
plays a role in -catenin signaling and in the regulation
of apoptosis. Here we demonstrate that phosphorylation
of PS1 is regulated by two independent signaling path-
ways involving protein kinase (PK) A and PKC and that
both kinases can directly phosphorylate the large hy-
drophilic domain of PS1 in vitro and in cultured cells. A
phosphorylation site at serine residue 346 was identi-
fied that is selectively phosphorylated by PKC but not
by PKA. This site is localized within a recognition motif
for caspases, and phosphorylation strongly inhibits pro-
teolytic processing of PS1 by caspase activity during
apoptosis. Moreover, PS1 phosphorylation reduces the
progression of apoptosis. Our data indicate that phos-
phorylation/dephosphorylation at the caspase recogni-
tion site provides a mechanism to reversibly regulate
properties of PS1 in apoptosis.
Neuronal cell death underlies the pathogenesis of Alzhei-
mer’s disease, and it has been suggested that apoptotic mech-
anisms are involved in this process (1). Classical features
of apoptosis, including DNA fragmentation, activation of
caspases, and cleavage of poly(ADP-ribose) polymerase
(PARP)1 can be detected in Alzheimer’s disease brains, and it
has been shown that the amyloid -peptide (A), a major con-
stituent of -amyloid plaques, can induce apoptosis of neuronal
cells (1).
A derives from the larger -amyloid precursor protein
(APP) by sequential cleavages mediated by - and -secre-
tases (2, 3). The presenilin (PS) 1 and PS2 proteins are criti-
cally involved in -secretase activity (4) and might represent
members of a family of aspartic proteases that catalyze
cleavage of proteins within their transmembrane domains
(5–7). Pathogenic mutations in the PS genes that cause familial
forms of early onset Alzheimer’s disease lead to increased pro-
duction of the 42 amino acid form of A that aggregates much
faster than A40 to form insoluble fibrils (8). PS are multi-pass
transmembrane proteins that undergo endoproteolytic process-
ing to generate stable N-terminal (NTF) and C-terminal frag-
ments (CTF) (9). The fragments assemble to a high molecular
weight complex with other proteins including nicastrin (10),
APH-1 a/b (11), and PEN-2 (12) that are also essential for
-secretase activity and Notch signaling (13, 14).
In addition to the involvement in intramembranous proteol-
ysis, other functions have been attributed to PS proteins, in-
cluding the regulation of calcium homeostasis (15–17), cell
adhesion (18, 19), and the subcellular trafficking of several
membrane proteins, like TrkB, telencephalin, and APP (20–
22). Moreover, PS1 binds to -catenin and negatively regulates
Wnt signaling (23–25). Several lines of evidence indicate that
PS proteins are also involved in apoptosis (1). Initially, a gene
trap analysis for anti-apoptotic factors revealed a C-terminal
sequence of PS2 (26). It was also demonstrated that inhibition
of PS1 expression in cultured tumor cells or mice strains with
spontaneous tumor development induces a higher rate of apo-
ptosis (27). Both PS1 and PS2 are also substrates for caspases
in vitro and in cultured cells (28–30), and the C-terminal cleav-
age product of PS2 has been shown to inhibit Fas-induced
apoptosis (31). On the other hand, proapoptotic activities of PS
proteins have also been reported (32–34). Notably, FAD-asso-
ciated mutations in the PS genes have been shown to sensitize
cells to several apoptotic stimuli (35–37).
In this study we investigated whether phosphorylation of
PS1 modulates its role in apoptosis. PS1 was found to be
phosphorylated at serine residue 346 by PKC. The phosphoryl-
ation at this site regulates the caspase-mediated cleavage of
PS1 and inhibits the progression of apoptosis.
MATERIALS AND METHODS
cDNAs and Fusion Proteins—The phosphorylation site mutants of
PS1 were generated by PCR techniques using appropriate oligonucleo-
tides. The resulting PCR fragments were subcloned into the EcoRI/XhoI
restriction sites of pcDNA3.1 containing a zeocine resistance gene (In-
vitrogen). The fusion proteins of the maltose-binding protein and the
hydrophilic loop domain of PS1 have been described earlier (38).
Cell Culture and Transfection—Human embryonic kidney (HEK) 293
cells, green monkey kidney Cos-7 cells, human cervix carcinoma cells
(HeLa), and human mammary carcinoma fibroblasts (MCF-7 cells)
were cultured in Dulbecco’s modified Eagle’s medium with Glutamax
(Invitrogen) supplemented with 10% fetal calf serum (Invitrogen). The
HEK293 cell line stably overexpressing APP695 (39) and the MCF-7
cells stably expressing Fas (40) have been described previously. Trans-
fection of cells with PS1 cDNAs was carried out using FuGENE 6
reagent (Roche Applied Science) according to the supplier’s instruc-
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tions. Single cell clones were generated by selection in 200 g/ml zeo-
cine (Invitrogen).
Antibodies, Immunoprecipitation, and Immunoblotting—The anti-
bodies 3027, 2953 (41), 3711 (38), APS18 (42), NT1 (43), and BI.HF5C
(44), have been described previously. Monoclonal antibody against Fas
was kindly provided by Drs. P. Krammer and M. E. Peter (German
Cancer Research Center, Heidelberg, Germany), and polyclonal anti-
PARP antibody was obtained from Roche Applied Science. The proteins
were detected by Western immunoblotting using an enhanced chemi-
luminescence technique (Amersham Biosciences).
Phosphorylation of PS1—Phosphorylation of PS1 in cultured cells
was carried out as described earlier (41). Protein kinase or phosphatase
activities were modulated by the addition of the activators or inhibitors
as indicated in the respective experiment. In vitro phosphorylation
assays with purified PKA from bovine heart (kindly provided by Dr. V.
Kinzel) or with rat brain PKC (Biomol) were carried out as described
previously (38). Recombinant protein representing the loop region of
PS1 (amino acids 263–407) was used as substrate. Phosphorylation
reactions were started by the addition of 10 M [-32P]ATP and allowed
to proceed for 20 min at 32 °C. To control the kinase activities, parallel
phosphorylation reactions were carried out using histone (0.5 mg/ml;
Sigma) as protein substrate. The reactions were stopped by the addition
of SDS sample buffer.
Two-dimensional Phosphopeptide Mapping—32P-Labeled PS1 was
analyzed by two-dimensional phosphopeptide mapping according to
Boyle et al. (45) after digestion with trypsin (sequencing grade; Roche
Applied Science). In some experiments synthetic peptides representing
phosphorylated PS1 were added to the digest as indicated in the re-
spective experiments. The peptides were dissolved in 300 l of pH 1.9
buffer (7.8% (v/v) glacial acetic acid, 2.5% (v/v) formic acid (88%)) and
spotted onto a cellulose-coated TLC plate (Merck). After thin layer
electrophoresis for 20 min at 1 kV (first dimension), chromatography
with phosphochromatography buffer (37.5% (v/v) n-butanol, 25% (v/v)
pyridine, 6.1% (v/v) glacial acetic acid) was carried out (second dimen-
sion). The radiolabeled peptides were detected by autoradiography. To
visualize synthetic peptides, TLC plates were stained with ninhydrin.
In Vitro Cleavage by Caspases—One g of the respective fusion
proteins or 5 g of synthetic peptides were incubated at 37 °C for 4 h in
25 l of cleavage assay buffer (20 mM Hepes, pH 7.2, 100 mM sodium
chloride, 10 mM magnesium chloride, 1 mM EDTA, 0.1% CHAPS, 10%
sucrose) in the presence or absence of 20 ng of recombinant active
caspase-3 (PharMingen). The reactions were terminated by shock freez-
ing in liquid nitrogen. Cleavage of fusion proteins was analyzed by
Western immunoblotting, and cleavage of synthetic peptides was ana-
lyzed by matrix-assisted laser desorption ionization time-of-flight mass
spectrometry.
Matrix-assisted Laser Desorption Ionization Time-of-Flight Mass
Spectrometry—Synthetic PS1 peptides, after incubation in the presence
or absence of recombinant caspase-3, were desalted and purified by
microbore reversed phase high pressure liquid chromatography. The
peptides were eluted with an acetonitrile gradient in 0.1% trifluoroace-
tic acid on a 150  1.0 mm Vydac C18 column. 0.5 l of selected peak
fractions were applied onto the dried matrix spot. The matrix consisted
of 13 mg of nitrocellulose (Bio-Rad) and 20 mg of -cyano 4-hydroxy-
cinnamic acid (Sigma) dissolved in 1 ml of acetone:isopropanol 2:3 (v/v).
0.5 l of the matrix solution was applied onto the sample target. The
samples were analyzed with a Perseptive Biosystems (Framingham,
MA) Voyager Elite delayed extraction time-of-flight reflectron mass
spectrometer at an acceleration voltage of 20 kV. Calibration was in-
ternal to the samples with Des-Arg-Bradykinin (Sigma) and adreno-
corticotropic hormone (18–38) (Sigma).
Induction and Analysis of Apoptosis—HeLa, HEK293, or Cos-7 cells
were treated with 1 M staurosporine (STS) for the time points indi-
cated. Apoptosis of MCF-7 cells overexpressing Fas was induced by
incubation with monoclonal anti-Fas antibody (2 g/ml). Progression of
apoptosis was monitored by the following parameters: (a) Cleavage of
poly(ADP-ribose) polymerase (PARP) was analyzed by immunoblotting
(46). (b) Early changes in membrane permeability were detected by cell
staining with 1 g/ml Hoechst 33342 (Sigma) (47). The accumulation of
the dye in apoptotic cells was analyzed using an inverted fluorescence
microscope (Leica DMIL, Wetzlar, Germany) equipped with a band pass
excitation filter of 340–380 nm and a long pass emission filter of 425
nm. (c) Caspase-3 activity was measured as described previously (48).
In brief, the cells were exposed to 1 M STS for 2 or 6 h, respectively.
After determination of cell numbers, the cells were homogenized in 750
l of caspase-3 assay buffer (10 mM Hepes/KOH, pH 7.4, 2 mM EDTA,
FIG. 1. PKA and PKC independently
regulate phosphorylation of PS1. A,
HEK293 cells were incubated in phos-
phate-free medium for 1 h in the presence
or absence of H-89 (inhibitor of PKA) or
of GF109203X (inhibitor of PKA) as
indicated prior to the addition of
[32P]orthophosphate. To activate PKA
and PKC 5 M forskolin or 1 M PDBu,
respectively, was added to the labeling
medium (see “Materials and Methods”).
After 2 h the cells were lysed, and PS1
CTF was immunoprecipitated with anti-
body 3027. Immunoprecipitates were sep-
arated by SDS-PAGE and transferred to
polyvinylidene difluoride membrane. The
radiolabeled proteins were detected by
autoradiography (upper panel). After ex-
posure, PS1 CTFs were detected by im-
munoblotting with antibody 3027 on the
same membrane (lower panel). Note that
phosphorylated forms of PS1 CTF
(CTF(P)) migrate slower in SDS gels as
compared with unphosphorylated forms
(CTF). The asterisks indicate weakly
phosphorylated PS1 CTFs that might be
phosphorylated by kinases distinct from
PKA and PKC (see text). B, recombinant
proteins representing amino acids 263–
407 of PS1 (rec. PS1loop) were incubated
with PKA and PKC in the presence of
[-32P]ATP for the time periods indicated.
The reaction mixtures were separated by
SDS-PAGE, and the radiolabeled proteins
were detected by autoradiography.
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0,1% CHAPS, 5 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride,
10 g/ml pepstatin A, 20 g/ml leupeptin, 10 g/ml aprotinin). The
homogenate was centrifuged at 100,000  g at 4 °C, and the superna-
tant was incubated with the fluorogenic caspase-3 tetrapeptide-sub-
strate Ac-DEVD-amino-4-methylcoumarin (Calbiochem, Bad Soden,
Germany) at a final concentration of 20 M. The cleavage of the
caspase-3 substrate was followed by determination of emission at 460
nm after excitation at 390 nm using a fluorescence plate reader.
RESULTS
Phosphorylation of PS1 by PKA and PKC—Previously, we
and others have shown that phosphorylation of the PS1 CTF
increases upon activation of PKC or PKA (41, 49). To investi-
gate whether PKC and PKA independently regulate phospho-
rylation of PS1, we pharmacologically activated or inactivated
these kinases in HEK293 cells during incubation with
[32P]orthophosphate. Activation of PKC with phorbol 12,13-
dibutyrate (PDBu) results in strong increase of phosphate in-
corporation into the PS1 CTF (Fig. 1A, upper panel). Consistent
with previous results (41, 49), phosphorylation of the PS1 CTF
induces a slower migration in SDS gels resulting in an appar-
ent molecular mass shift from  20 to  23 kDa (Fig. 1A, lower
panel). Cell treatment with the PKC inhibitor GF109203X se-
lectively suppresses the PDBu-induced phosphorylation of PS1
CTF. In contrast, the PKA inhibitor H-89 had no significant
effect on PDBu induced phosphorylation, indicating that PDBu
selectively increases PKC-dependent phosphorylation of PS1.
Activation of PKA by cell treatment with forskolin also in-
creases phosphorylation of PS1. In contrast to the PDBu-in-
duced phosphorylation, the forskolin-induced phosphorylation
of PS1 is strongly suppressed by the PKA inhibitor H-89 but
not by the PKC inhibitor GF109203X (Fig. 1A). These results
demonstrate that phosphorylation of the PS1 CTF can be reg-
ulated by two independent signaling pathways involving PKA
or PKC, respectively.
The hydrophilic loop region between TM6 and TM7 of PS1
contains several consensus recognition sites for these kinases
(Fig. 2A). We therefore tested whether both kinases can phos-
phorylate this domain in vitro using a recombinant protein that
represents amino acids 263–407 of PS1 as a substrate. Both
PKA and PKC readily phosphorylate the recombinant PS1
sequence in a time-dependent manner (Fig. 1B), indicating that
the hydrophilic loop region of PS1 is a substrate for both
kinases.
FIG. 2. PS1 is phosphorylated at Ser346 by PKC. A, alignment of PS1 loop amino acid sequences from several mammalian species. Potential
phosphorylation sites within the minimal consensus sequence for PKC ((R/K)XS) are indicated by arrowheads. The amino acid sequence of human
PS1 also contains a recognition motif for PKA (RRX(S/T)) at Ser310. Note that the recognition motif at Ser346 is conserved in all mammalian species
(boxed). The cleavage site for caspase is indicated by an arrow. B, recombinant proteins representing amino acids 263–407 of PS1 WT, S310A and
S346A were incubated with PKA or PKC in the presence of [-32P]ATP for 20 min. The radiolabeled proteins were detected by autoradiography
(upper panels), and the total proteins were visualized by Coomassie staining (lower panels). Note that PKA-mediated phosphorylation of PS1
containing the S310A mutation is completely abolished. C, HEK293 cells were labeled with [32P]orthophosphate in the presence of PDBu, and PS1
CTF was isolated by immunoprecipitation with antibody 3027 and SDS-PAGE. After blotting to polyvinylidene difluoride membrane, radiolabeled
PS1 CTF was digested with trypsin in the presence of the synthetic phosphopeptide DS(p)HLGPLR, which represents a tryptic digestion product
of PS1 (amino acids 345–352). After two-dimensional separation of the digestion products, radiolabeled peptides were detected by autoradiography
(left panel). The synthetic peptide was visualized by staining the plate with ninhydrin (middle panel). Overlay of the autoradiogram with the
stained TLC plate demonstrated co-migration of one in vivo phosphorylated peptide with the synthetic peptide (indicated by dashed circle (right
panel)).
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It has been demonstrated that PS1 is predominantly phos-
phorylated on serine residue(s) (41). A computer-assisted data
base search revealed that Ser346 is conserved in PS1 of mam-
malian species but not in PS2 (Fig. 2A). This residue is pre-
ceded by an arginine residue at the 2 position and therefore
fulfills the minimal primary sequence requirements for phos-
phorylation by PKC (Fig. 2A). Importantly Ser346 is located at
the caspase recognition site of PS1 that is cleaved during apo-
ptosis by caspase activity (28, 29). In addition, a potential
phosphorylation site for PKA (RRXS) was identified at Ser310
(Fig. 2A).
To test whether Ser310 and Ser346 represent phosphorylation
sites for PKA and/or PKC in vitro, we substituted these resi-
dues by alanine residues and used the respective recombinant
proteins representing amino acids 263–407 of PS1 as sub-
strates. PKA-mediated phosphorylation of PS1 is completely
inhibited by mutation of Ser310 but not affected by the S346A
mutant (Fig. 2B), indicating that Ser310 is the sole PKA phos-
phorylation site within the hydrophilic loop domain of PS1. The
PKC-mediated phosphorylation is inhibited with both mutants,
indicating that PKC can phosphorylate at least two distinct
sites within this region in vitro (Fig. 2B). Because Ser346, in
contrast to Ser310, is fully conserved between mammalian spe-
cies, we analyzed phosphorylation of Ser346 in more detail.
To assess whether Ser346 is an in vivo phosphorylation site,
HEK293 cells were labeled with [32P]orthophosphate in the
presence of PDBu to activate PKC, and PS1 CTF was isolated
by immunoprecipitation. Two-dimensional phosphopeptide
mapping was carried out in the presence of a synthetic phos-
phopeptide representing a tryptic digestion product of PS1 in a
phosphorylated state (D(p)SHLGPLR; amino acids 345–352 of
PS1). 32P-Labeled peptides were detected by autoradiography
(Fig. 2B, left panel), and the synthetic phosphopeptide was
visualized by staining with ninhydrin (Fig. 2B, middle panel).
The overlay of both images reveals co-migration of a 32P-la-
beled tryptic digestion product of in vivo phosphorylated PS1
with the synthetic phosphopeptide (Fig. 2B, right panel), indi-
cating that Ser346 is phosphorylated in cultured cells. The
additional 32P-labeled spot might represent another tryptic
peptide containing another phosphorylation site (e.g. Ser310,
Ser353, or Ser357) (50) or a partially digested product phospho-
rylated at Ser346.
Phosphorylation at Ser346 Inhibits Caspase-mediated Cleav-
age—Ser346 is located in the P-1 position to the cleavage site
for caspases that cleave PS1 after Asp345 during apoptosis
(28–30). To analyze the effect of phosphorylation of PS1 on the
proteolytic processing by caspases during apoptosis, we first
used HeLa cells, a cell type that reveals several apoptotic
features including cleavage of endogenous PARP and endoge-
nous PS1 CTF (46). After induction of apoptosis by treatment
with STS, cleavage of PARP and endogenous PS1 was analyzed
by Western immunoblotting. In untreated cells mainly full-
length PARP and only very low amounts of cleavage products
are detected (Fig. 3A, upper panel). The amount of the charac-
FIG. 3. Cleavage of PS1 CTF during staurosporine induced apoptosis is inhibited by phosphorylation. A, HeLa cells were incubated
with 1 M STS for the time periods indicated. Endogenous PARP (upper panel) and PS1 CTF (lower panel) from cell lysates were detected by
Western immunoblotting. Both PARP and PS1 CTF are processed upon staurosporine treatment to yield smaller proteins indicated as PARPcleaved
and PS1 CTFcasp. B, HeLa cells were incubated for 16 h in the presence or absence of STS and/or 1 M OA as indicated. Cleavage of PARP and PS1
CTF was analyzed as described above. C, MCF-7 cells stably expressing Fas were incubated with (anti-Fas) or without () monoclonal anti-Fas
antibody in the absence (ctr.) or presence of 1 M OA. A minor cleavage product of PS1 in anti-Fas antibody-treated cells that is not significantly
affected by OA treatment is indicated by an asterisk.
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teristic cleavage product of PARP increases in a time-depend-
ent manner upon treatment with STS. After 4 h of treatment
with staurosporine, PARP is almost completely converted (Fig.
3A, upper panel). STS treatment also induces cleavage of the
endogenous PS1 CTF with similar kinetics, resulting in the
generation of a smaller fragment (PS1 CTFcasp; Fig. 3A, lower
panel). In contrast to PARP, the PS1 CTF is not fully converted,
even after 24 h of treatment with STS. These results are
consistent with previous studies, indicating that some fractions
of PS1 are resistant to caspase activity even after long treat-
ment with apoptotic stimuli (28–30). To investigate the role of
PS1 phosphorylation on its turnover during apoptosis, the cells
were incubated with okadaic acid (OA) that inhibits protein
dephosphorylation by protein phosphatases 1 and 2A. Very low
amounts of cleavage products of PARP and the PS1 CTF are
detected in untreated cells (Fig. 3B). Cell treatment with OA
alone induces cleavage of PARP to some extent, indicating that
this reagent lead to caspase activation. However, cleavage of
PS1 CTF is hardly detectable under these conditions. STS has
a much stronger effect on induction of apoptosis and leads to
almost complete conversion of PARP and of significant portions
of PS1 CTF to yield CTFcasp. Notably, the presence of OA
during staurosporine-induced apoptosis reduces cleavage of the
PS1 CTF, whereas cleavage of PARP is not inhibited (Fig. 3B).
These data suggest that phosphorylated PS1 might be pro-
tected against caspase-mediated cleavage during apoptosis of
HeLa cells. Very similar results were also obtained with Cos-7
cells (data not shown).
To test another experimental paradigm of apoptosis, MCF-7
cells stably overexpressing Fas were incubated in the presence
or absence of cross-linking monoclonal anti-Fas antibody (Fig.
3C). In untreated MCF-7 cells, very little if any PS1 CTFcasp is
detected, whereas robust amounts of endogenous PS1 CTF are
present. Cell treatment with anti-Fas antibody for 6 h results
in the accumulation of the characteristic PS1 CTFcasp, indicat-
ing processing of PS1 CTF by caspase activity during Fas-
mediated apoptosis (Fig. 3C). The presence of OA significantly
reduces the generation of PS1 CTFcasp during Fas-mediated
apoptosis (Fig. 3C). Taken together, these data indicate that
cleavage of PS1 by caspases during apoptosis is very likely to be
controlled by phosphorylation. Because this effect is observed
in different cell types and different experimental paradigms of
apoptosis, the inhibition of caspase-mediated cleavage of PS1
by phosphorylation appears to be a general phenomenon. How-
ever, OA itself is a modulator of apoptosis by interference with
other dephosphorylation events (51). These data therefore do
not rule out the possibility that the observed inhibition of
caspase-mediated cleavage of PS1 is due to indirect effects
of OA.
To prove that phosphorylation of Ser346 indeed inhibits
caspase-mediated cleavage, we used synthetic peptides that
represent amino acids 341–350 of PS1 and contain Ser346 in
unphosphorylated or phosphorylated state. The in vitro cleav-
age of these peptides by recombinant caspase-3 was analyzed
by matrix-assisted laser desorption ionization time-of-flight
mass spectrometry. Caspase-3 efficiently cleaves the unphos-
phorylated peptide (MH  1212.54) after Asp345, as indicated
by the detection of monomeric (MH  613.28) and dimeric
FIG. 4. Phosphorylation at Ser346 inhibits cleavage by caspase-3 in vitro. Synthetic peptides EAQRDSHLGPC (A and B) and
EAQRDS(p)HLGPC (C and D) representing amino acid sequence 341–350 of PS1 with unphosphorylated and phosphorylated Ser346, respectively, were
incubated in the absence (A and C) or presence (B and D) of recombinant caspase-3 for 4 h at 37 °C. The samples were subjected to MADLI-TOF
MS. The unphosphorylated peptide (MH  1212.54 Da) is readily cleaved by caspase-3, as indicated by the presence of the monomeric (MH 
613.28 Da) and dimeric (MH  1223.53 Da) C-terminal cleavage products (B). In contrast the phosphorylated peptide (MH  1292.48 Da) is
resistant against caspase-3 activity (C and D). *, adreno-corticotropic hormone (MH  2465.20 Da) and Des-Arg-bradykinin (MH  904.47 Da)
were added as internal standards. The extraneous peak (m/z  624.0) could not be attributed to a sequence related to synthetic peptide.
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(MH  1223.53) forms of the C-terminal cleavage product
SHLGPC (Fig. 4, A and B). In contrast, the phosphorylated
peptide is resistant against caspase-3 activity (Fig. 4, C and D),
demonstrating that phosphorylation at Ser346 inhibits caspase-
mediated cleavage of PS1.
We next tested whether the effect of phosphorylation can be
mimicked by substitution of Ser346 by a negatively charged
amino acid. Fusion proteins containing the hydrophilic loop
domain (amino acids 263–407) of PS1 WT or the S346A or
S346E substitutions were used as substrates for in vitro
caspase assays. Both the PS1 WT and the S346A mutation are
readily cleaved by caspase-3 in vitro (Fig. 5A). In contrast,
substitution of Ser346 by a glutamate residue strongly inhibits
caspase-3-mediated cleavage of PS1 CTF, thereby mimicking
the effect of phosphorylation at this site. By using the phos-
phorylation site mutants we were able to investigate the effect
of PS1 phosphorylation in living cells without further pharma-
cological modulation of kinase/phosphatase activities that
might cause unspecific side effects.
HEK293 cells were stably transfected with cDNAs of human
PS1 WT, PS1 S346A, or PS1 S346E, and the respective proteins
were detected by Western immunoblotting. Consistent with
previous reports (9), endogenous PS1 is predominantly de-
tected as an 30-kDa NTF and an 20-kDa CTF, whereas the
full-length protein is hardly detectable (Fig. 5B). We also de-
tected endogenous PS2 CTF in untransfected cells. Overexpres-
sion of PS1 variants leads to the detection of full-length pro-
teins and of the respective NTFs and CTFs, indicating that the
S346A and S346E variants are proteolytically processed like
the PS1 WT protein. Moreover, all variants replace endogenous
PS proteins (Fig. 5B), indicating incorporation into the charac-
teristic PS containing high molecular weight protein complexes
(9, 42). Notably, substitution of Ser346 by glutamate induces a
shift in the apparent molecular mass of the PS1 CTF in SDS
gels, very similar to that observed for PS1 WT upon cell treat-
ment with PDBu (Fig. 5B; compare with Fig. 1). These data
indicate that introduction of a negatively charged amino acid
has a similar effect on the conformation of PS1 CTF as
phosphorylation.
To test the caspase-mediated cleavage of PS1 WT, S346A, or
S346E, the cells were incubated in the presence or absence of
STS. Very little if any PS1 CTFcasp is detected in all untreated
cell lines (Fig. 5C). STS treatment leads to the accumulation of
CTFcasp derived from both PS1 WT and the S346A mutant (Fig.
5C). In contrast, the generation of PS1 CTFcasp is strongly
inhibited in cells expressing the PS1 S346E mutant, indicating
FIG. 5. Inhibition of caspase-medi-
ated cleavage of PS1 by mimicking
phosphorylated Ser346. A, fusion pro-
teins maltose-binding protein-PS1 loop
WT, S346A, or S346E were incubated in
the presence () or absence () of recom-
binant caspase-3. The samples were sep-
arated by SDS-PAGE and PS1 detected
by Western immunoblotting with anti-
body 3027. B, HEK293 cells were stably
transfected with cDNAs encoding PS1
WT, S346A, or S346E. PS1 and PS2 pro-
teins were detected by immunoprecipita-
tion (IP) and Western immunoblotting
(blot) with the antibodies indicated. Note
that PS1 CTF derived from the S346E
mutant migrates slower in SDS gels as
compared with the WT and S346A muta-
tion, similar to phosphorylated PS1 CTF
(see Fig. 1). C, cells expressing PS1 WT,
S346A, and S346E were incubated in the
presence or absence of 1 M STS for 16 h,
and PS1 CTFs were detected by Western
immunoblotting. Similar data were ob-
tained with other single cell clones and
with stable pooled clones.
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protection of this mutant against caspase-mediated cleavage
during apoptosis. Mutations of the phosphorylation site at
Ser310 do not inhibit caspase-mediated cleavage during STS-
induced apoptosis (data not shown). Taken together, these data
provide evidence that phosphorylation of PS1 at Ser346, as
mimicked by introduction of negatively charged glutamate res-
idue, strongly inhibits proteolytic processing of PS1 CTF by
caspase activity during apoptosis of cultured cells.
Phosphorylation of PS1 Regulates the Progression of Apopto-
sis—We took advantage of these cell lines stably overexpressing
PS1 WT or the phosphorylation site mutants to assess the effect
of PS1 phosphorylation on apoptosis. The cells were incubated in
the presence or absence of STS and then stained with Hoechst
33342 to selectively detect cells with permeabilized membranes
caused by early apoptosis (47). In untreated cultures low num-
bers of positive cells are detected (Fig. 6, A and B). STS treatment
increases the number of bright nuclei in PS1 WT-expressing cells
and to a stronger extent in cells expressing PS1 S346A, indicat-
ing the induction of apoptosis. In contrast, the cells expressing
the PS1 S346E mutant are less sensitive to the apoptotic stimu-
lus, as indicated by the lower number of bright nuclei after STS
treatment (Fig. 6, A and B). Very similar data were also obtained
when the increase in cell death by STS treatment was deter-
mined by trypan blue exclusion (Fig. 6C). These data indicate
that phosphorylation of PS1 at Ser346 decreases the susceptibility
of cells to apoptotic stimuli.
The progression of apoptosis critically depends on the acti-
vation of caspases. We therefore tested whether the observed
differences in apoptotic cell death that depend on the phospho-
rylation state of PS1 are associated with different levels of
active caspase-3. Upon treatment with STS for 2 h, caspase-3
activity increases in cells expressing PS1 WT (Fig. 6D). Highest
levels of caspase-3 activity are detected in cells expressing PS1
S346A that can not be phosphorylated at this site. Importantly,
only a slight increase in caspase-3 activity is detected in PS1
S346E-expressing cells after STS treatment, indicating that
phosphorylation of PS1, as mimicked by the S346E mutation,
decreases the activation of caspase-3.
DISCUSSION
We demonstrate that phosphorylation of the PS1 CTF at
Ser346 inhibits its caspase-mediated cleavage and modulates
the progression of apoptosis. Ser346 is phosphorylated by PKC
in vitro and in cultured cells, whereas PKA exclusively phos-
phorylates Ser310. However, phosphorylation of Ser310 does not
inhibit the caspase-mediated cleavage of PS1 (data not shown),
and the biological function of this phosphorylation event re-
mains to be determined in further experiments.
In previous studies, phosphorylation of PS1 at serine resi-
dues 353, 354, and 357 has also been reported (50, 52). These
sites are phosphorylated by GSK3 or CDK5 in vitro. Our data
are in line with these findings, because two-dimensional phos-
phopeptide mapping and in vitro phosphorylation experiments
revealed additional phosphorylation sites in PS1 beside Ser346
(Fig. 2). We also find that S346A and S310A mutants can still
be phosphorylated by GSK3 in vitro (data not shown). Using
synthetic peptides as substrates, we demonstrate that phos-
phorylation of Ser346 strongly inhibits caspase-3-mediated
cleavage of PS1. Treatment of cells with OA that inhibits de-
phosphorylation of PS1 also reduces its cleavage in several cell
types including HeLa, Cos-7, and MCF-7 cells and upon dis-
tinct apoptotic stimuli, indicating a general role of PS1 phos-
phorylation in the regulation of caspase-mediated cleavage
during apoptosis. However, OA affects multiple signaling
events and also interferes with regulatory pathways in apopto-
sis (51). To circumvent indirect effects of OA treatment in
analyzing the function of PS1 phosphorylation at Ser346, we
generated cell lines stably expressing PS1 mutants that mimic
phosphorylated or unphosphorylated variants. This strategy
allowed us to investigate the biological effect of phosphoryla-
FIG. 6. Phosphorylation of PS1 inhibits progression of apoptosis and the activation of caspase-3.0. A and B, HEK293 cells stably
expressing PS1 WT, S346A, or S346E were incubated for 2 h in the absence or presence of 1 M STS and then stained with Hoechst 33342.
Photomicrographs (A) are representative for three independent experiments that were quantified in the graph (B). C, quantification of cell death
by STS treatment as determined by trypan blue exclusion (see “Materials and Methods”). The values represent the means  S.D. of four
independent experiments and are expressed as increases in positive cells as compared with untreated cells. *, p  0.025. D, measurement of
caspase-3 activity was carried out as described under “Materials and Methods.” The values represent the means  S.D. of 4–6 independent
experiments. **, p  0.001. Highly similar data were obtained in experiments with independent single cell clones and with stable mixed clones.
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tion without additional pharmacological manipulation of ki-
nase or phosphatase activities. Indeed, the substitution of
Ser346 by negatively charged amino acids inhibits cleavage of
PS1 in vitro and in cultured cells, thereby mimicking the effect
of phosphorylation.
The observed mechanism of cleavage inhibition of PS1 is
highly similar to that of PS2 (46). In contrast to PS1, which was
found to be phosphorylated at its caspase cleavage site by PKC,
PS2 is phosphorylated by the second messenger-independent
casein kinases 1 or 2 (53), indicating separate regulatory path-
ways for PS1 and PS2 (38). However, further studies are
needed to reveal the role of the distinct regulatory pathways
that regulate phosphorylation of PS1 and PS2.
It has been demonstrated that protein phosphorylation is
involved in the regulation of apoptosis (51), and anti-apoptotic
functions for PKC have been reported. Activation of (54, 55)
PKC inhibits apoptosis in several cell types (51, 56). Moreover,
PKC is up-regulated in a wide range of cancers (51, 57). How-
ever, also pro-apoptotic activities of PKC have been reported,
and it is assumed that the different functions of this kinase in
apoptosis might be exerted by distinct isoenzymes (51). In this
study phosphorylation of PS1 is strongly inhibited by
GF109203X, which predominantly targets PKC and PKCI
(58). Notably, these isoforms can inhibit apoptosis in a number
of cell lines and are up-regulated in a large number of cancers
(51). The molecular targets involved in the PKC-mediated in-
hibition of apoptosis are not fully defined. It has been shown
that PKC can phosphorylate Bcl-2 (59), which might increase
the anti-apoptotic functions of this protein. Our study indicates
that the anti-apoptotic function of PKC might also involve
phosphorylation of PS1.
It has been suggested that the PS1 CTF derived by caspase-
mediated cleavage (CTFcasp) promotes apoptosis (29, 30), allow-
ing a positive feedback regulation of caspase-mediated cleavage
of PS1. As demonstrated in this study, PKC-mediated phospho-
rylation of PS1 strongly reduces the generation of CTFcasp and
might thereby retard the progression of apoptosis by inhibiting
this feedback regulation. We also found that cells expressing
PS1 S346E have decreased caspase-3 activity in early stages of
apoptosis, suggesting that PS1 phosphorylation interferes with
the activation of this or an upstream caspase. It should be
noted that PS1 phosphorylation does not completely inhibit the
progression of STS-induced apoptosis. Rather, PS1 might be a
modulator involved in the initiation phase of apoptosis that is
regulated by phosphorylation/dephosphorylation.
Previous studies have shown that the large hydrophilic do-
main of PS1, in which we localized phosphorylation, is dispen-
sable for -secretase activity (60). In line with this, we did not
observe a significant effect of PS1 phosphorylation at Ser346 on
the -secretory processing of APP (data not shown). It has also
been shown that the PS1 loop binds -catenin and regulates
Wnt signaling (24, 61). The binding region of PS1 for -catenin
is localized between amino acids 340–371 (62). Although Ser346
is located within this binding domain, phosphorylation of PS1
does not significantly affect its binding to -catenin (data not
shown). Thus, phosphorylation at Ser346 appears to be mainly
responsible for regulation of the apoptotic properties of PS1
independent of its other biological functions, like in the -secre-
tase cleavage of APP and the regulation of Wnt signaling.
Despite the large number of proteins that become cleaved
during apoptosis by caspase activity, only some of them have
been shown to be protected by phosphorylation, including Bid
(63), IB (64), PS2 (46), and the PS2-interacting protein calse-
nilin (65). Phosphorylation of proteins at caspase recognition
sites provides a mechanism to regulate their proteolytic cleav-
age and at least in some cases their functions in apoptosis.
Changes in the phosphorylation and/or dephosphorylation of
PS1 might therefore contribute to the pathogenesis of Alzhei-
mer’s disease by altering the susceptibility of brain neurons to
apoptotic stimuli.
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